<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622724</url>
  </required_header>
  <id_info>
    <org_study_id>FPCLI002</org_study_id>
    <secondary_id>2014-005260-15</secondary_id>
    <nct_id>NCT02622724</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)</brief_title>
  <acronym>INTEREST</acronym>
  <official_title>A Phase III Double-blind, Randomised, Parallel-Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human IFN Beta-1a) and Placebo in the Treatment of Patients With Moderate or Severe Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Faron Pharmaceuticals Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seventh Framework Programme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Faron Pharmaceuticals Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study effectiveness and safety of a new drug FP-1201-lyo (recombinant human
      interferon beta-1a) is compared to placebo. Investigation is conducted with patients who have
      acute respiratory distress syndrome (ARDS). The new drug is expected to reduce the time which
      a patient need to be on the ventilator and improve patient's chances of survival. Currently
      there are no approved drugs for treating moderate or severe ARDS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III clinical study to investigate the efficacy and safety of FP-1201-lyo
      (recombinant human interferon [IFN] beta-1a) compared to placebo in patients diagnosed with
      moderate or severe acute respiratory distress syndrome (ARDS). Primary objective is to
      demonstrate the efficacy of FP-1201-lyo in improving the clinical course and outcome based on
      survival and need for mechanical ventilation. Currently there are no approved drugs for
      treating moderate or severe ARDS patients.

      FP-1201-lyo is a lyophilised powder form of recombinant human IFN beta-1a reconstituted in
      water for injection and is administered intravenously.

      Recombinant human IFN beta-1a is an approved treatment for patients for other indication and
      its safety profile in such patients is well characterised.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Day 90 results indicate IMP did not reduce mortality or ventilator free days
  </why_stopped>
  <start_date type="Actual">December 23, 2015</start_date>
  <completion_date type="Actual">May 23, 2018</completion_date>
  <primary_completion_date type="Actual">May 17, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Endpoint (VFDsurv; All-cause Mortality and Number of Days Free of Mechanical Ventilation) at Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>VFDsurv is a composite measure of all-cause mortality and the number of days free of mechanical ventilation (VFDsurv) within 28 days among survivors. Ventilator-free days (VFDs) correspond to those days when unassisted breathing (UAB) was possible for a complete calendar day. UAB was defined as: spontaneously breathing with face mask, nasal prong oxygen or room air, T-piece breathing, tracheostomy mask breathing, CPAP less than or equal to 5 cmH2O without pressure support or intermittent mandatory ventilation assistance, use of CPAP or BIPAP solely for sleep apnoea management. A patient was reported as ventilator-free after 2 consecutive calendar days of unassisted breathing (a VFD value of 0 is assigned to patients who die without initiating UAB or who require more than 28 days of mechanical ventilation. All patients who die before Day28 are assigned a VFDsurv value of -1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: All-cause Mortality</measure>
    <time_frame>At Day 28</time_frame>
    <description>Fatalities, mortality all-causes from randomisation up to Day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: Mortality in ICU</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>All-cause mortality for subjects who died in Intensive Care Units up to Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: Mortality in Hospital</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>This is the number of subjects who died in hospital (i.e. outside of Intensive Care Units) up to Day 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Secondary Efficacy Endpoints: Days Free of Organ Failure</measure>
    <time_frame>Day 28 or last day in intensive care unit [ICU] if patient has left the ICU earlier than Day 28</time_frame>
    <description>The total number of days free of organ failure by Sequential Organ Failure Assessment (SOFA) methodology. Overall, the median number of days free of organ failure was 0 days in both the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Secondary Efficacy Endpoints: Days Free of Renal Support</measure>
    <time_frame>Day 28</time_frame>
    <description>Days without renal support (any renal support was documented). Overall, the median number of days free of renal support was 28 days in the active group and 27 days in the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Secondary Efficacy Endpoints: Days Free of Vasoactive Support</measure>
    <time_frame>Day 28</time_frame>
    <description>Days without vasoactive support. The vasoactive support included catecholamine and non-catecholamine vasopressors, inotropes and vasodilating agents.
Overall, the median number of days free of vasoactive support was 20 days in the active group and 21 days in the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Secondary Efficacy Endpoint: Days Free of Mechanical Ventilation</measure>
    <time_frame>Day 28</time_frame>
    <description>The total number of days free of mechanical ventilation has been derived from the Patient Status report recorded on each day during the 28-day period. Patients who died during this period have been assigned a value of zero. This variable differs from the calculated &quot;Ventilation Free Days (VFD) endpoint, which contribute to the VDFsurv primary efficacy endpoint as it require additional conditions of unassisted breathing (UAB) to be met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Secondary Efficacy Endpoints: Number of ICU-free Days</measure>
    <time_frame>Day 28</time_frame>
    <description>Number of Intensive Care Unit free days up to Day 28, i.e. the patient is no longer receiving care in ICU. Patients who die during this period have been assigned a value of zero for the number of ICU care free days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Secondary Efficacy Endpoints: Number of Days in Hospital</measure>
    <time_frame>Day 28</time_frame>
    <description>Hospitalisation days (including the stay at Intensive Care Units). Patients who died during this period have been assigned a value of 28 for the number of days in ICU or in hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Safety: Adverse Events and Deaths</measure>
    <time_frame>AEs up to Day 28, only related after Day 28 and deaths up to Day 360</time_frame>
    <description>Adverse events (AE) up to Day 28. Per protocol, AEs occurring after Day 28 if the investigator considered a causal relationship with the study drug as well as all deaths up to Day 360 were reported. Treatment-emergent AEs (TEAEs) were defined as AEs that begins or worsens in intensity after at least one dose of study drug has been administered. Serious AEs (SAEs) were defined as any untoward medical occurrence that at any dose resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: Presence of Neutralising Antibodies to IFN Beta-1a</measure>
    <time_frame>Baseline and Day 28 (or last day in intensive care unit [ICU] or at withdrawal, if earlier)</time_frame>
    <description>The immunological response to FP-1201-lyo was assessed by monitoring presence of anti-drug binding antibodies (BAbs) and neutralising antibodies (NAbs) to IFN beta-1a on pre-dose Day 1 and at Day 28, the last day in ICU or early termination (if earlier). The BAbs were determined first, and if present, the NAbs were also determined. Presence of BAbs and NAbs were summarised categorically, using positive/negative classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy Endpoint: Evaluation of Pharmacodynamic (PD) Using Myxovirus Resistance Protein A (MxA) Biomarker</measure>
    <time_frame>From baseline to Day 14</time_frame>
    <description>Evaluation of MxA biomarker change from baseline to D14 between treatments arms over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Efficacy Endpoint: Change in Quality of Life From Baseline to Day 180</measure>
    <time_frame>Change from baseline to Day 180</time_frame>
    <description>Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to long term follow-up (Day 180 visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Efficacy Endpoints Relating to Respiratory Functioning (FEV1)</measure>
    <time_frame>Day 180</time_frame>
    <description>Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Efficacy Endpoints Relating to Neurological Functioning (6MWT)</measure>
    <time_frame>Day 180</time_frame>
    <description>The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % conf.interval) for the overall treatment difference was analysed.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluation of Safety: Vital Signs - Heart Rate</measure>
    <time_frame>From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
    <description>Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point.
No statistical analyses were made for vital signs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Safety: Vital Signs - Body Temperature</measure>
    <time_frame>From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
    <description>Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point.
No statistical analyses were made for vital signs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Safety: Vital Signs - Blood Pressure</measure>
    <time_frame>From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
    <description>Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point.
No statistical analyses were made for vital signs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Safety: Physical Examination</measure>
    <time_frame>From baseline to Last Observation Performed (D28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
    <description>Physical examination data (covering the major body systems; general appearance, head [ear, nose and throat], cardiovascular, eyes, respiratory, abdomen, urogenital, musculoskeletal, neurological, lymph nodes and skin) were categorized as &quot;normal&quot;; &quot;abnormal, not clinically significant;&quot; &quot;abnormal, clinically significant&quot; or &quot;not done&quot;. Physical examinations were performed at Screening, then at the Last day in ICU and Day 28 (Out of ICU) or Early Termination, from which the last observation performed is derived. The changes from baseline to the last observations performed are categorized as &quot;no change&quot;, &quot;change clinically significant&quot;; &quot;change not clinically significant&quot;, &quot;not done&quot;.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Safety: Laboratory Results</measure>
    <time_frame>From baseline to Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
    <description>Laboratory safety assessments of biochemistry, haematology and urinalysis were performed daily during the stay at ICU. Laboratory data were classified according to normal ranges as out of range (OOR; not clinically significant), OOR (clinically significant), or OOR (clinically significant and an AE). Laboratory test results were summarised by actual results by baseline and last observation period.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Pharmacoeconomics: Days Free of Organ Failure</measure>
    <time_frame>Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
    <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Pharmacoeconomics: Days Free of Renal Support</measure>
    <time_frame>Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
    <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Pharmacoeconomics: Days Free of Vasoactive Support</measure>
    <time_frame>Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
    <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Pharmacoeconomics: Days Free of Mechanical Ventilation</measure>
    <time_frame>Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
    <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Pharmacoeconomics: Number of ICU-free Days</measure>
    <time_frame>Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
    <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of Pharmacoeconomics: Number of Days in Hospital</measure>
    <time_frame>Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
    <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Variables Relating to Efficacy: Composite Endpoint (Mortality and Days Free of Mechanical Ventilation) at Day 90</measure>
    <time_frame>Within 90 days</time_frame>
    <description>Composite endpoint including mortality and days free of mechanical ventilation (VFDsurv) within 90 days among survivors. Ventilation Free Survival at Day 90 has been classified as Dead, Alive but on a ventilator and Alive and breathing unassisted</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the Treatment-specific Exploratory Biomarker Cluster of Differentiation 73 (CD73) Concentration</measure>
    <time_frame>From baseline to Day 14</time_frame>
    <description>Evaluation of Cluster of differentiation 73 (CD73) change from baseline to D14 between treatments arms over time.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Levels of Potential Inflammatory Markers (PIMs)</measure>
    <time_frame>From baseline to Day 14</time_frame>
    <description>Evaluation of potential inflammatory markers (PIMs) change from baseline to D14 between treatments arms over time. Potential biomarkers included IL-1ra, IL-6, FGF basic, IP-10 and TNF-α.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacogenetic Analysis</measure>
    <time_frame>Anytime from baseline to Day 28</time_frame>
    <description>An optional genetic sample was analysed for subjects based on a separate consent. A carrier frequency was analysed for a C/T polymorphism (rs9984723) located in the 3'PRIME_UTR/intron region of IFNAR2-gene, which encodes the beta chain for the IFN-alpha/beta receptor and encompasses a regulatory motif for the glucocorticoid receptor. Biomarker responders were defined by a 3-fold elevation in MxA and a 2-fold in CD73 in comparison to baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory, Extended Long-term Follow-up: Overall Mortality at Day 360</measure>
    <time_frame>Day 360 /termination of study</time_frame>
    <description>Fatalities; as the study was terminated early, the assessment time point for mortality at Day 360 was not reached. Therefore only the overall mortality at study termination is presented.</description>
  </other_outcome>
  <other_outcome>
    <measure>Extended Long-term Follow-up Exploratory Endpoint: Change in Quality of Life From Baseline to Day 360</measure>
    <time_frame>Change from baseline to Day 360</time_frame>
    <description>Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to extended long term follow-up (Day 360 visit).</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurological Functioning (6MWT) at Extended Long-term Follow-up</measure>
    <time_frame>Day 360</time_frame>
    <description>The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % confidence intervals) for the overall treatment difference was analysed.</description>
  </other_outcome>
  <other_outcome>
    <measure>Extended Long-term Follow-up Endpoint: Respiratory Functioning (FEV1) at Day 360</measure>
    <time_frame>Day 360</time_frame>
    <description>Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">301</enrollment>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <arm_group>
    <arm_group_label>FP-1201-lyo 10 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.
Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FP-1201-lyo Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>FP-1201-lyo Placebo will be administered once daily as an intravenous bolus injection for 6 days.
Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1a</intervention_name>
    <description>Investigational drug</description>
    <arm_group_label>FP-1201-lyo 10 μg</arm_group_label>
    <other_name>FP-1201-lyo</other_name>
    <other_name>Traumakine</other_name>
    <other_name>ATC code L03AB07</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for investigational drug</description>
    <arm_group_label>FP-1201-lyo Placebo</arm_group_label>
    <other_name>FP-1201-lyo Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All patients must be intubated and mechanically ventilated to diagnose ARDS and be eligible
        for the study

          1. Patient has a diagnosis of moderate or severe ARDS according to the Berlin definition
             of ARDS:

               -  Acute onset of respiratory failure within 1 week of a known clinical insult or
                  new or worsening respiratory symptoms

               -  Respiratory failure associated with known ARDS risk factors and not fully
                  explained by either cardiac failure or fluid overload (an objective assessment of
                  cardiac failure or fluid overload is needed if no risk factors for ARDS [moderate
                  or severe ARDS] are present)

               -  Radiological abnormalities on chest X-ray or on computerised tomography scan,
                  i.e., bilateral opacities that are not fully explained by effusions, nodules,
                  masses or lobar/lung collapse

               -  Hypoxaemia:

                    -  Moderate ARDS: PaO2/FiO2 &gt;100 mmHg (&gt;13.3 kPa) to ≤200 mmHg (≤26.6 kPa) with
                       positive end expiratory pressure (PEEP) ≥5 cmH2O

                    -  Severe ARDS: PaO2/FiO2 ≤100 mmHg (≤13.3 kPa) with positive end expiratory
                       pressure [PEEP] ≥5 centimeter of water [cmH2O]

          2. The radiological and hypoxaemia criteria (1.3 and 1.4) must be met within the same
             24-hour period. The time of onset of ARDS is when the last of the two specified ARDS
             criteria is met

          3. Administration of the first dose of study drug must be planned to take place within 48
             hours of moderate or severe ARDS diagnosis

          4. Patient is intubated and mechanically ventilated

          5. A signed informed consent form from the patient or the patient's personal legal
             representative or a professional legal representative must be available

          6. Patient is aged ≥18 years

        Exclusion Criteria:

          1. Woman known to be pregnant, lactating or with a positive (urine or serum test) or
             indeterminate (serum test) pregnancy test

          2. Patient is simultaneously taking part in another pharmacotherapy protocol

          3. Patient is not expected to survive for 24 hours

          4. Patient has an underlying clinical condition where, in the opinion of the
             Investigator, it would be extremely unlikely that the patient would come off
             ventilation, e.g., motor neurone disease, Duchenne muscular dystrophy or rapidly
             progressive interstitial pulmonary fibrosis

          5. Patient has severe chronic obstructive pulmonary disease requiring long-term home
             oxygen therapy or mechanical ventilation (non-invasive ventilation or via tracheotomy)
             except for continuous positive airway pressure (CPAP) or bi-level positive airway
             pressure used solely for sleep-disordered breathing

          6. Patient has congestive heart failure, defined as New York Heart Association class IV

          7. Patient has acute left ventricular failure

          8. Patient has liver failure (Child-Pugh grade C)

          9. Patient has received any prior interferon

         10. Patient has known hypersensitivity to natural or recombinant IFN beta or to any of the
             excipients

         11. Patient is receiving renal dialysis therapy for chronic renal failure

         12. Patient is receiving extra-corporeal membrane oxygenation, high-frequency oscillatory
             ventilation or any form of extra-corporeal lung support

         13. Patient has had any form of mechanical ventilation (invasive or non-invasive,
             excluding CPAP alone) for longer than 48 hours prior to the diagnosis of ARDS.
             Non-invasive ventilation has to be continuously applied for at least 12 hours per day
             in these 48 hours

         14. Patient has burns to ≥15% of their total body surface area
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey Bellingan, MD</last_name>
    <role>Study Director</role>
    <affiliation>University College London Hospitals, NHS, London, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>V Marco Ranieri, Prof. MD</last_name>
    <role>Study Director</role>
    <affiliation>Universita La Sapeinza Policlinico Umberto I, Rome, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus Hospital</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>B-1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charleroi Site Hôpital Civil Marie Curie</name>
      <address>
        <city>Lodelinsart</city>
        <zip>B-6042</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dinant Godinne UCL Namur</name>
      <address>
        <city>Yvoir</city>
        <zip>B-5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Králové</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Kralovske Vinohrady</name>
      <address>
        <city>Praha 10</city>
        <zip>10034</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Usti nad Labem</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>40011</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>FI-70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>FI-33521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Central Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <state>Alsace</state>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'Orléans</name>
      <address>
        <city>Orléans</city>
        <state>Loiret</state>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU D'Angers</name>
      <address>
        <city>Angers</city>
        <state>Pays-de-la-Loire</state>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU De Poitiers</name>
      <address>
        <city>Poitiers</city>
        <state>Poitou-Charentes</state>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <state>Rhône</state>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles-Nicolle</name>
      <address>
        <city>Rouen</city>
        <state>Seine-Maritime</state>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord AP-HM</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin, Réanimation Médicale Hospitalisation</name>
      <address>
        <city>Paris</city>
        <state>Île-de-France</state>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg Klinik für Anästhesiologie</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn Klinik und Poliklinik für Anästhesiologie</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Klinik für Anästhesiologie und Intensivmedizin</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen Klinik für Anästhesiologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf Klinik für Intesivmedizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln Klinikum Merheim</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Leipzig Klinik und Poliklinik für Anäesthesiologie und Intensivtherapie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Sant' Anna</name>
      <address>
        <city>Cona</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Monza</name>
      <address>
        <city>Monza</city>
        <zip>209000</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Roma &quot;La Sapienza&quot;</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu I Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario del Henares</name>
      <address>
        <city>Coslada</city>
        <zip>28822</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Getafe</name>
      <address>
        <city>Getafe</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Dr Negrin</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Mútua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary University Hospitals, Bristol Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals, NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's University Hospitals, NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital Imperial College Healthcre NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital St Mary's Hospital, Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W21NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancashire Treaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Preston</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital, University Hospital Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 24, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2015</study_first_posted>
  <results_first_submitted>August 28, 2019</results_first_submitted>
  <results_first_submitted_qc>March 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2020</results_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARDS, human</keyword>
  <keyword>Acute Respiratory Distress Syndrome</keyword>
  <keyword>Respiratory Insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferon beta-1a</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02622724/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02622724/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FP-1201-lyo 10 μg</title>
          <description>FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.
Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection.
Interferon beta-1a: Investigational drug</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo will be administered once daily as an intravenous bolus injection for 6 days.
Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection.
Placebo: Placebo for investigational drug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Randomised</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="155"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Short-Term Follow-Up (Day 28)</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Long-Term Follow-Up (Day 90)</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Long-Term Follow-Up (Day 180)</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-UP, withdrawal of consent</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early termination of study</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>A total of 296 subjects received at least 1 dose of study treatment (301 subjects fulfilled all criteria and were randomly assigned in a 1:1 ratio to FP-1201-lyo and placebo, but 5 subjects were not dosed).The Full Analysis Set (FAS) consisted of the 296 randomised and treated subjects who received 1 or more doses study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>FP-1201-lyo 10 μg</title>
          <description>FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.
Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection.
Interferon beta-1a: Investigational drug</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo will be administered once daily as an intravenous bolus injection for 6 days.
Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection.
Placebo: Placebo for investigational drug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="144"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="296"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.3" spread="17.2"/>
                    <measurement group_id="B2" value="58.4" spread="14.0"/>
                    <measurement group_id="B3" value="58.4" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="103"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American Indian/Alaskan</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Arab</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian-Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other or not reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Endpoint (VFDsurv; All-cause Mortality and Number of Days Free of Mechanical Ventilation) at Day 28</title>
        <description>VFDsurv is a composite measure of all-cause mortality and the number of days free of mechanical ventilation (VFDsurv) within 28 days among survivors. Ventilator-free days (VFDs) correspond to those days when unassisted breathing (UAB) was possible for a complete calendar day. UAB was defined as: spontaneously breathing with face mask, nasal prong oxygen or room air, T-piece breathing, tracheostomy mask breathing, CPAP less than or equal to 5 cmH2O without pressure support or intermittent mandatory ventilation assistance, use of CPAP or BIPAP solely for sleep apnoea management. A patient was reported as ventilator-free after 2 consecutive calendar days of unassisted breathing (a VFD value of 0 is assigned to patients who die without initiating UAB or who require more than 28 days of mechanical ventilation. All patients who die before Day28 are assigned a VFDsurv value of -1).</description>
        <time_frame>Day 28</time_frame>
        <population>Full Analysis Set (FAS), 296 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.
Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection.
Interferon beta-1a: Investigational drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo will be administered once daily as an intravenous bolus injection for 6 days.
Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection.
Placebo: Placebo for investigational drug</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint (VFDsurv; All-cause Mortality and Number of Days Free of Mechanical Ventilation) at Day 28</title>
          <description>VFDsurv is a composite measure of all-cause mortality and the number of days free of mechanical ventilation (VFDsurv) within 28 days among survivors. Ventilator-free days (VFDs) correspond to those days when unassisted breathing (UAB) was possible for a complete calendar day. UAB was defined as: spontaneously breathing with face mask, nasal prong oxygen or room air, T-piece breathing, tracheostomy mask breathing, CPAP less than or equal to 5 cmH2O without pressure support or intermittent mandatory ventilation assistance, use of CPAP or BIPAP solely for sleep apnoea management. A patient was reported as ventilator-free after 2 consecutive calendar days of unassisted breathing (a VFD value of 0 is assigned to patients who die without initiating UAB or who require more than 28 days of mechanical ventilation. All patients who die before Day28 are assigned a VFDsurv value of -1).</description>
          <population>Full Analysis Set (FAS), 296 subjects.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="-1" upper_limit="26"/>
                    <measurement group_id="O2" value="8.5" lower_limit="-1" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A non-parametric analysis has been used as the data distribution was skewed. This involved a generalised Wilcoxon rank sum-based stratification test which assigns ranks within strata and compares two treatments within strata (Van Elteren hypothesis test).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8219</p_value>
            <method>Van Elteren hypothesis test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Endpoint: All-cause Mortality</title>
        <description>Fatalities, mortality all-causes from randomisation up to Day 28</description>
        <time_frame>At Day 28</time_frame>
        <population>Full Analysis Set (FAS) defined as all randomised subjects that received atleast one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Endpoint: All-cause Mortality</title>
          <description>Fatalities, mortality all-causes from randomisation up to Day 28</description>
          <population>Full Analysis Set (FAS) defined as all randomised subjects that received atleast one dose of study drug.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" lower_limit="19" upper_limit="34"/>
                    <measurement group_id="O2" value="23" lower_limit="17" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Endpoint: Mortality in ICU</title>
        <description>All-cause mortality for subjects who died in Intensive Care Units up to Day 28.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Endpoint: Mortality in ICU</title>
          <description>All-cause mortality for subjects who died in Intensive Care Units up to Day 28.</description>
          <population>Full Analysis Set</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" lower_limit="19" upper_limit="34"/>
                    <measurement group_id="O2" value="23.0" lower_limit="17" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Endpoint: Mortality in Hospital</title>
        <description>This is the number of subjects who died in hospital (i.e. outside of Intensive Care Units) up to Day 28.</description>
        <time_frame>Up to Day 28</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Endpoint: Mortality in Hospital</title>
          <description>This is the number of subjects who died in hospital (i.e. outside of Intensive Care Units) up to Day 28.</description>
          <population>Full Analysis Set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Secondary Efficacy Endpoints: Days Free of Organ Failure</title>
        <description>The total number of days free of organ failure by Sequential Organ Failure Assessment (SOFA) methodology. Overall, the median number of days free of organ failure was 0 days in both the treatment groups.</description>
        <time_frame>Day 28 or last day in intensive care unit [ICU] if patient has left the ICU earlier than Day 28</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Secondary Efficacy Endpoints: Days Free of Organ Failure</title>
          <description>The total number of days free of organ failure by Sequential Organ Failure Assessment (SOFA) methodology. Overall, the median number of days free of organ failure was 0 days in both the treatment groups.</description>
          <population>Full Analysis Set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="28"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Secondary Efficacy Endpoints: Days Free of Renal Support</title>
        <description>Days without renal support (any renal support was documented). Overall, the median number of days free of renal support was 28 days in the active group and 27 days in the placebo group.</description>
        <time_frame>Day 28</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Secondary Efficacy Endpoints: Days Free of Renal Support</title>
          <description>Days without renal support (any renal support was documented). Overall, the median number of days free of renal support was 28 days in the active group and 27 days in the placebo group.</description>
          <population>Full Analysis Set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="0" upper_limit="28"/>
                    <measurement group_id="O2" value="27" lower_limit="0" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Secondary Efficacy Endpoints: Days Free of Vasoactive Support</title>
        <description>Days without vasoactive support. The vasoactive support included catecholamine and non-catecholamine vasopressors, inotropes and vasodilating agents.
Overall, the median number of days free of vasoactive support was 20 days in the active group and 21 days in the placebo group.</description>
        <time_frame>Day 28</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Secondary Efficacy Endpoints: Days Free of Vasoactive Support</title>
          <description>Days without vasoactive support. The vasoactive support included catecholamine and non-catecholamine vasopressors, inotropes and vasodilating agents.
Overall, the median number of days free of vasoactive support was 20 days in the active group and 21 days in the placebo group.</description>
          <population>Full Analysis Set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="0" upper_limit="28"/>
                    <measurement group_id="O2" value="21" lower_limit="1" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Secondary Efficacy Endpoint: Days Free of Mechanical Ventilation</title>
        <description>The total number of days free of mechanical ventilation has been derived from the Patient Status report recorded on each day during the 28-day period. Patients who died during this period have been assigned a value of zero. This variable differs from the calculated &quot;Ventilation Free Days (VFD) endpoint, which contribute to the VDFsurv primary efficacy endpoint as it require additional conditions of unassisted breathing (UAB) to be met.</description>
        <time_frame>Day 28</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Secondary Efficacy Endpoint: Days Free of Mechanical Ventilation</title>
          <description>The total number of days free of mechanical ventilation has been derived from the Patient Status report recorded on each day during the 28-day period. Patients who died during this period have been assigned a value of zero. This variable differs from the calculated &quot;Ventilation Free Days (VFD) endpoint, which contribute to the VDFsurv primary efficacy endpoint as it require additional conditions of unassisted breathing (UAB) to be met.</description>
          <population>Full Analysis Set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="0" upper_limit="26"/>
                    <measurement group_id="O2" value="9" lower_limit="0" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Van Elteren hypothesis test was used as the distribution was non-normal and negatively skewed by patients who are assigned scores of zero in the event of death.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4678</p_value>
            <method>Van Elteren p-values</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Secondary Efficacy Endpoints: Number of ICU-free Days</title>
        <description>Number of Intensive Care Unit free days up to Day 28, i.e. the patient is no longer receiving care in ICU. Patients who die during this period have been assigned a value of zero for the number of ICU care free days.</description>
        <time_frame>Day 28</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Secondary Efficacy Endpoints: Number of ICU-free Days</title>
          <description>Number of Intensive Care Unit free days up to Day 28, i.e. the patient is no longer receiving care in ICU. Patients who die during this period have been assigned a value of zero for the number of ICU care free days.</description>
          <population>Full Analysis Set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="0" upper_limit="24"/>
                    <measurement group_id="O2" value="3.5" lower_limit="0" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Other Secondary Efficacy Endpoints: Number of Days in Hospital</title>
        <description>Hospitalisation days (including the stay at Intensive Care Units). Patients who died during this period have been assigned a value of 28 for the number of days in ICU or in hospital.</description>
        <time_frame>Day 28</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Other Secondary Efficacy Endpoints: Number of Days in Hospital</title>
          <description>Hospitalisation days (including the stay at Intensive Care Units). Patients who died during this period have been assigned a value of 28 for the number of days in ICU or in hospital.</description>
          <population>Full Analysis Set</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="8" upper_limit="28"/>
                    <measurement group_id="O2" value="28" lower_limit="8" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Safety: Adverse Events and Deaths</title>
        <description>Adverse events (AE) up to Day 28. Per protocol, AEs occurring after Day 28 if the investigator considered a causal relationship with the study drug as well as all deaths up to Day 360 were reported. Treatment-emergent AEs (TEAEs) were defined as AEs that begins or worsens in intensity after at least one dose of study drug has been administered. Serious AEs (SAEs) were defined as any untoward medical occurrence that at any dose resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was an important medical event.</description>
        <time_frame>AEs up to Day 28, only related after Day 28 and deaths up to Day 360</time_frame>
        <population>The analysis population included all participants who were randomized and received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Safety: Adverse Events and Deaths</title>
          <description>Adverse events (AE) up to Day 28. Per protocol, AEs occurring after Day 28 if the investigator considered a causal relationship with the study drug as well as all deaths up to Day 360 were reported. Treatment-emergent AEs (TEAEs) were defined as AEs that begins or worsens in intensity after at least one dose of study drug has been administered. Serious AEs (SAEs) were defined as any untoward medical occurrence that at any dose resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was an important medical event.</description>
          <population>The analysis population included all participants who were randomized and received at least 1 dose of study treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with AE considered related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Endpoint: Presence of Neutralising Antibodies to IFN Beta-1a</title>
        <description>The immunological response to FP-1201-lyo was assessed by monitoring presence of anti-drug binding antibodies (BAbs) and neutralising antibodies (NAbs) to IFN beta-1a on pre-dose Day 1 and at Day 28, the last day in ICU or early termination (if earlier). The BAbs were determined first, and if present, the NAbs were also determined. Presence of BAbs and NAbs were summarised categorically, using positive/negative classification.</description>
        <time_frame>Baseline and Day 28 (or last day in intensive care unit [ICU] or at withdrawal, if earlier)</time_frame>
        <population>Full Analysis Set, the subjects who had laboratory evaluation done. Subjects were analysed for IFN beta NAbs only if BAbs were present.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Endpoint: Presence of Neutralising Antibodies to IFN Beta-1a</title>
          <description>The immunological response to FP-1201-lyo was assessed by monitoring presence of anti-drug binding antibodies (BAbs) and neutralising antibodies (NAbs) to IFN beta-1a on pre-dose Day 1 and at Day 28, the last day in ICU or early termination (if earlier). The BAbs were determined first, and if present, the NAbs were also determined. Presence of BAbs and NAbs were summarised categorically, using positive/negative classification.</description>
          <population>Full Analysis Set, the subjects who had laboratory evaluation done. Subjects were analysed for IFN beta NAbs only if BAbs were present.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Presence of BAbs to IFN β-1a at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presence of BAbs to IFN β-1a at Day28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presence of NAbs to IFN β-1a at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presence of NAbs to IFN β-1a at Day28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy Endpoint: Evaluation of Pharmacodynamic (PD) Using Myxovirus Resistance Protein A (MxA) Biomarker</title>
        <description>Evaluation of MxA biomarker change from baseline to D14 between treatments arms over time.</description>
        <time_frame>From baseline to Day 14</time_frame>
        <population>Subjects from Full Analysis Set population for whom samples were available; analysis of last observation performed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Endpoint: Evaluation of Pharmacodynamic (PD) Using Myxovirus Resistance Protein A (MxA) Biomarker</title>
          <description>Evaluation of MxA biomarker change from baseline to D14 between treatments arms over time.</description>
          <population>Subjects from Full Analysis Set population for whom samples were available; analysis of last observation performed.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
                <count group_id="O2" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="63.3"/>
                    <measurement group_id="O2" value="7.8" spread="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) model using Type III sums of squares with Treatment, Severity, and Country fixed effect factors, Baseline as covariate</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Efficacy Endpoint: Change in Quality of Life From Baseline to Day 180</title>
        <description>Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to long term follow-up (Day 180 visit).</description>
        <time_frame>Change from baseline to Day 180</time_frame>
        <population>Subjects from Full Analysis Set population who completed QoL questionnaire at Baseline and Day 180.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Efficacy Endpoint: Change in Quality of Life From Baseline to Day 180</title>
          <description>Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to long term follow-up (Day 180 visit).</description>
          <population>Subjects from Full Analysis Set population who completed QoL questionnaire at Baseline and Day 180.</population>
          <units>change score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10" lower_limit="-55" upper_limit="70"/>
                    <measurement group_id="O2" value="-5" lower_limit="-60" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Efficacy Endpoints Relating to Respiratory Functioning (FEV1)</title>
        <description>Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.</description>
        <time_frame>Day 180</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Efficacy Endpoints Relating to Respiratory Functioning (FEV1)</title>
          <description>Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.</description>
          <population>Full Analysis Set</population>
          <units>%FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.2" spread="21.1"/>
                    <measurement group_id="O2" value="79.5" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Efficacy Endpoints Relating to Neurological Functioning (6MWT)</title>
        <description>The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % conf.interval) for the overall treatment difference was analysed.</description>
        <time_frame>Day 180</time_frame>
        <population>All subjects in Full Analysis Set population who performed atleast one 6MWT test at Day 180 visit. Furthest distance walked during the two tests was analysed using an ANOVA model.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Efficacy Endpoints Relating to Neurological Functioning (6MWT)</title>
          <description>The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % conf.interval) for the overall treatment difference was analysed.</description>
          <population>All subjects in Full Analysis Set population who performed atleast one 6MWT test at Day 180 visit. Furthest distance walked during the two tests was analysed using an ANOVA model.</population>
          <units>maximum distance walked (meters)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449" spread="174"/>
                    <measurement group_id="O2" value="424" spread="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment effect was analysed using ANOVA parameter estimates (Least Squares Means and 95% Confidence Intervals) for the overall treatment difference for maximum distance walked on Day 180.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Least Squares Mean</param_type>
            <param_value>31.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-37.7</ci_lower_limit>
            <ci_upper_limit>99.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluation of Safety: Vital Signs - Heart Rate</title>
        <description>Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point.
No statistical analyses were made for vital signs.</description>
        <time_frame>From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
        <population>Safety Population - no statistical analyses were made for vital signs.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Safety: Vital Signs - Heart Rate</title>
          <description>Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point.
No statistical analyses were made for vital signs.</description>
          <population>Safety Population - no statistical analyses were made for vital signs.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart Rate, bpm : Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.4" spread="22.2"/>
                    <measurement group_id="O2" value="94.8" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate, bpm : LOP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" spread="18.3"/>
                    <measurement group_id="O2" value="92.7" spread="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluation of Safety: Vital Signs - Body Temperature</title>
        <description>Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point.
No statistical analyses were made for vital signs.</description>
        <time_frame>From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
        <population>Safety Population - no statistical analyses were made for vital signs.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Safety: Vital Signs - Body Temperature</title>
          <description>Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point.
No statistical analyses were made for vital signs.</description>
          <population>Safety Population - no statistical analyses were made for vital signs.</population>
          <units>degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Body Temperature, degrees C : Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.1" spread="1.1"/>
                    <measurement group_id="O2" value="37.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body Temperature, degrees C : LOP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" spread="0.9"/>
                    <measurement group_id="O2" value="36.8" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluation of Safety: Vital Signs - Blood Pressure</title>
        <description>Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point.
No statistical analyses were made for vital signs.</description>
        <time_frame>From baseline to Last Observation Performed (Day 28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
        <population>Safety Population - no statistical analyses were made for vital signs.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Safety: Vital Signs - Blood Pressure</title>
          <description>Vital signs were measured supine pre-dose on Day 1 (baseline) and daily up to Day 28 while the patient was in the ICU. The results at baseline and at last observation performed (LOP) were summarized overall by treatment, variable and time point.
No statistical analyses were made for vital signs.</description>
          <population>Safety Population - no statistical analyses were made for vital signs.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure, mmHg: Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.6" spread="20.4"/>
                    <measurement group_id="O2" value="110.2" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure, mmHg : LOP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.3" spread="22.8"/>
                    <measurement group_id="O2" value="120.3" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure, mmHg : Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.9" spread="12.9"/>
                    <measurement group_id="O2" value="55.6" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure, mmHg : LOP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.1" spread="14.8"/>
                    <measurement group_id="O2" value="62.6" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Arterial Pressure, mmHg : Pre-Dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.5" spread="13.9"/>
                    <measurement group_id="O2" value="73.6" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Arterial Pressure, mmHg : LOP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" spread="15.5"/>
                    <measurement group_id="O2" value="80.8" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluation of Safety: Physical Examination</title>
        <description>Physical examination data (covering the major body systems; general appearance, head [ear, nose and throat], cardiovascular, eyes, respiratory, abdomen, urogenital, musculoskeletal, neurological, lymph nodes and skin) were categorized as &quot;normal&quot;; &quot;abnormal, not clinically significant;&quot; &quot;abnormal, clinically significant&quot; or &quot;not done&quot;. Physical examinations were performed at Screening, then at the Last day in ICU and Day 28 (Out of ICU) or Early Termination, from which the last observation performed is derived. The changes from baseline to the last observations performed are categorized as &quot;no change&quot;, &quot;change clinically significant&quot;; &quot;change not clinically significant&quot;, &quot;not done&quot;.</description>
        <time_frame>From baseline to Last Observation Performed (D28 or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
        <population>Safety population - no statistical analyses were made</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Safety: Physical Examination</title>
          <description>Physical examination data (covering the major body systems; general appearance, head [ear, nose and throat], cardiovascular, eyes, respiratory, abdomen, urogenital, musculoskeletal, neurological, lymph nodes and skin) were categorized as &quot;normal&quot;; &quot;abnormal, not clinically significant;&quot; &quot;abnormal, clinically significant&quot; or &quot;not done&quot;. Physical examinations were performed at Screening, then at the Last day in ICU and Day 28 (Out of ICU) or Early Termination, from which the last observation performed is derived. The changes from baseline to the last observations performed are categorized as &quot;no change&quot;, &quot;change clinically significant&quot;; &quot;change not clinically significant&quot;, &quot;not done&quot;.</description>
          <population>Safety population - no statistical analyses were made</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>General Appearance</title>
              <category_list>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ear, Nose and Throat</title>
              <category_list>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eyes</title>
              <category_list>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory</title>
              <category_list>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdomen</title>
              <category_list>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urogenital</title>
              <category_list>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal</title>
              <category_list>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurological</title>
              <category_list>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph nodes</title>
              <category_list>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <category_list>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular</title>
              <category_list>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Change, Not Clinically Significant</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not done</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluation of Safety: Laboratory Results</title>
        <description>Laboratory safety assessments of biochemistry, haematology and urinalysis were performed daily during the stay at ICU. Laboratory data were classified according to normal ranges as out of range (OOR; not clinically significant), OOR (clinically significant), or OOR (clinically significant and an AE). Laboratory test results were summarised by actual results by baseline and last observation period.</description>
        <time_frame>From baseline to Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
        <population>Safety Population -no statistical analyses were made</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Safety: Laboratory Results</title>
          <description>Laboratory safety assessments of biochemistry, haematology and urinalysis were performed daily during the stay at ICU. Laboratory data were classified according to normal ranges as out of range (OOR; not clinically significant), OOR (clinically significant), or OOR (clinically significant and an AE). Laboratory test results were summarised by actual results by baseline and last observation period.</description>
          <population>Safety Population -no statistical analyses were made</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Haemoglobin, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haemoglobin, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucocytes, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucocytes, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bicarbonate, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Protein, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Protein, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Glucose, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Glucose, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Blood, Pre-Dose</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urine Blood, LOP</title>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (NCS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>OOR (CS+AE)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not available/pt died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluation of Pharmacoeconomics: Days Free of Organ Failure</title>
        <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
        <time_frame>Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
        <population>Costs items from hospitals were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacoeconomics: Days Free of Organ Failure</title>
          <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
          <population>Costs items from hospitals were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluation of Pharmacoeconomics: Days Free of Renal Support</title>
        <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
        <time_frame>Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
        <population>Costs items from hospitals were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacoeconomics: Days Free of Renal Support</title>
          <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
          <population>Costs items from hospitals were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluation of Pharmacoeconomics: Days Free of Vasoactive Support</title>
        <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
        <time_frame>Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
        <population>Costs items from hospitals were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacoeconomics: Days Free of Vasoactive Support</title>
          <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
          <population>Costs items from hospitals were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluation of Pharmacoeconomics: Days Free of Mechanical Ventilation</title>
        <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
        <time_frame>Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
        <population>Costs items from hospitals were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacoeconomics: Days Free of Mechanical Ventilation</title>
          <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
          <population>Costs items from hospitals were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluation of Pharmacoeconomics: Number of ICU-free Days</title>
        <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
        <time_frame>Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
        <population>Costs items from hospitals were not collected</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacoeconomics: Number of ICU-free Days</title>
          <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
          <population>Costs items from hospitals were not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Evaluation of Pharmacoeconomics: Number of Days in Hospital</title>
        <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
        <time_frame>Day 28 (or last day in ICU if patient has left the ICU earlier than Day 28, or at withdrawal)</time_frame>
        <population>Costs items from hospitals were not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Pharmacoeconomics: Number of Days in Hospital</title>
          <description>Due to the study terminating early, costs items from hospitals were not collected and pharmacoeconomic analyses could not be done.</description>
          <population>Costs items from hospitals were not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory Variables Relating to Efficacy: Composite Endpoint (Mortality and Days Free of Mechanical Ventilation) at Day 90</title>
        <description>Composite endpoint including mortality and days free of mechanical ventilation (VFDsurv) within 90 days among survivors. Ventilation Free Survival at Day 90 has been classified as Dead, Alive but on a ventilator and Alive and breathing unassisted</description>
        <time_frame>Within 90 days</time_frame>
        <population>Full Analysis Set (discontinued not included).</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory Variables Relating to Efficacy: Composite Endpoint (Mortality and Days Free of Mechanical Ventilation) at Day 90</title>
          <description>Composite endpoint including mortality and days free of mechanical ventilation (VFDsurv) within 90 days among survivors. Ventilation Free Survival at Day 90 has been classified as Dead, Alive but on a ventilator and Alive and breathing unassisted</description>
          <population>Full Analysis Set (discontinued not included).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dead</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alive-on ventilator</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alive-breathing unassisted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in the Treatment-specific Exploratory Biomarker Cluster of Differentiation 73 (CD73) Concentration</title>
        <description>Evaluation of Cluster of differentiation 73 (CD73) change from baseline to D14 between treatments arms over time.</description>
        <time_frame>From baseline to Day 14</time_frame>
        <population>Subjects from Full Analysis Set population for whom samples were available; analysis of last observation performed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Treatment-specific Exploratory Biomarker Cluster of Differentiation 73 (CD73) Concentration</title>
          <description>Evaluation of Cluster of differentiation 73 (CD73) change from baseline to D14 between treatments arms over time.</description>
          <population>Subjects from Full Analysis Set population for whom samples were available; analysis of last observation performed.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="8.9"/>
                    <measurement group_id="O2" value="6.1" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Levels of Potential Inflammatory Markers (PIMs)</title>
        <description>Evaluation of potential inflammatory markers (PIMs) change from baseline to D14 between treatments arms over time. Potential biomarkers included IL-1ra, IL-6, FGF basic, IP-10 and TNF-α.</description>
        <time_frame>From baseline to Day 14</time_frame>
        <population>Subjects from Full Analysis Set population for whom samples were available; analysis of last observation performed.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Levels of Potential Inflammatory Markers (PIMs)</title>
          <description>Evaluation of potential inflammatory markers (PIMs) change from baseline to D14 between treatments arms over time. Potential biomarkers included IL-1ra, IL-6, FGF basic, IP-10 and TNF-α.</description>
          <population>Subjects from Full Analysis Set population for whom samples were available; analysis of last observation performed.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IL-1ra</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1830" spread="5252"/>
                    <measurement group_id="O2" value="1699" spread="4565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" spread="298"/>
                    <measurement group_id="O2" value="88" spread="584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FGF basic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37" spread="17"/>
                    <measurement group_id="O2" value="38" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IP-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1938" spread="3543"/>
                    <measurement group_id="O2" value="1762" spread="3894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-α</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68" spread="60"/>
                    <measurement group_id="O2" value="81" spread="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>IL -1ra - changes in levels from baseline to Day 14</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA estimates (LS means and a 95 % CI for the treatment difference) were presented for all numeric biomarker variables.</method_desc>
            <param_type>LS Means difference</param_type>
            <param_value>0</param_value>
            <ci_n_sides>1-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>IL- 6 - changes in levels from baseline to Day 14</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA estimates (LS means and a 95 % CI for the treatment difference) were presented for all numeric biomarker variables.</method_desc>
            <param_type>LS Means difference</param_type>
            <param_value>0</param_value>
            <ci_n_sides>1-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>FGF basic - changes in levels from baseline to Day 14</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA estimates (LS means and a 95% CI for the treatment difference) were presented for all numeric biomarker variables.</method_desc>
            <param_type>LS Means difference</param_type>
            <param_value>0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>IP-10 - changes in levels from baseline to Day 14.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA estimates (LS means and a 95 % CI for the treatment difference) were presented for all numeric biomarker variables.</method_desc>
            <param_type>LS Means difference</param_type>
            <param_value>0</param_value>
            <ci_n_sides>1-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>TNF-α - changes in levels from baseline to Day 14</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA estimates (LS means and a 95 % CI for the treatment difference) were presented for all numeric biomarker variables.</method_desc>
            <param_type>LS Means difference</param_type>
            <param_value>0</param_value>
            <ci_n_sides>1-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pharmacogenetic Analysis</title>
        <description>An optional genetic sample was analysed for subjects based on a separate consent. A carrier frequency was analysed for a C/T polymorphism (rs9984723) located in the 3'PRIME_UTR/intron region of IFNAR2-gene, which encodes the beta chain for the IFN-alpha/beta receptor and encompasses a regulatory motif for the glucocorticoid receptor. Biomarker responders were defined by a 3-fold elevation in MxA and a 2-fold in CD73 in comparison to baseline.</description>
        <time_frame>Anytime from baseline to Day 28</time_frame>
        <population>Only subjects with consent for a genetic sample were analysed. Carriers of the C-allele were analysed in biomarker responders compared to biomarker non-responders. 5 and 6 subjects failed to provide genotype information in analyses for responder and non-responders, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Biomarker Responder</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Biomarker Non-responder</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacogenetic Analysis</title>
          <description>An optional genetic sample was analysed for subjects based on a separate consent. A carrier frequency was analysed for a C/T polymorphism (rs9984723) located in the 3'PRIME_UTR/intron region of IFNAR2-gene, which encodes the beta chain for the IFN-alpha/beta receptor and encompasses a regulatory motif for the glucocorticoid receptor. Biomarker responders were defined by a 3-fold elevation in MxA and a 2-fold in CD73 in comparison to baseline.</description>
          <population>Only subjects with consent for a genetic sample were analysed. Carriers of the C-allele were analysed in biomarker responders compared to biomarker non-responders. 5 and 6 subjects failed to provide genotype information in analyses for responder and non-responders, respectively.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-allele carrier</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-allele non-carrier</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.007</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Exploratory, Extended Long-term Follow-up: Overall Mortality at Day 360</title>
        <description>Fatalities; as the study was terminated early, the assessment time point for mortality at Day 360 was not reached. Therefore only the overall mortality at study termination is presented.</description>
        <time_frame>Day 360 /termination of study</time_frame>
        <population>Full Analysis Set, but the study was terminated early. The mortality numbers include 3 study subjects who had SAEs with an onset before the first dose of IMP and who subsequently died.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Exploratory, Extended Long-term Follow-up: Overall Mortality at Day 360</title>
          <description>Fatalities; as the study was terminated early, the assessment time point for mortality at Day 360 was not reached. Therefore only the overall mortality at study termination is presented.</description>
          <population>Full Analysis Set, but the study was terminated early. The mortality numbers include 3 study subjects who had SAEs with an onset before the first dose of IMP and who subsequently died.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Extended Long-term Follow-up Exploratory Endpoint: Change in Quality of Life From Baseline to Day 360</title>
        <description>Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to extended long term follow-up (Day 360 visit).</description>
        <time_frame>Change from baseline to Day 360</time_frame>
        <population>Subjects from Full Analysis Set population who completed QoL questionnaire at Baseline and Day 360. As the study was terminated early, only a limited amount of data were available at the post-baseline time point.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Extended Long-term Follow-up Exploratory Endpoint: Change in Quality of Life From Baseline to Day 360</title>
          <description>Quality of Life was assessed through EQ-5D-3L (EuroQol 5-Dimensions 3-Levels questionnaire). An EQ Visual Analogue Scale (VAS) total score (ranging from 0-100) was measured (0= Worst imaginable health state, 100= Best imaginable health state). The EQ-5D-3L VAS scores are numerically summarised as change from pre-dose (Day 1) to extended long term follow-up (Day 360 visit).</description>
          <population>Subjects from Full Analysis Set population who completed QoL questionnaire at Baseline and Day 360. As the study was terminated early, only a limited amount of data were available at the post-baseline time point.</population>
          <units>change score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-59" upper_limit="35"/>
                    <measurement group_id="O2" value="0" lower_limit="-80" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Neurological Functioning (6MWT) at Extended Long-term Follow-up</title>
        <description>The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % confidence intervals) for the overall treatment difference was analysed.</description>
        <time_frame>Day 360</time_frame>
        <population>All subjects in Full Analysis Set population who performed atleast one 6MWT test at Day 360, before the study was early terminated.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days</description>
          </group>
        </group_list>
        <measure>
          <title>Neurological Functioning (6MWT) at Extended Long-term Follow-up</title>
          <description>The 6-minute walk test (6MWT) measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes. According to the ERS/ATS technical standard to which the 6MWT was done, the walk test is done twice and the best result is used. It is an evaluation of the global and integrated responses of all systems involved during exercise, including the pulmonary and cardiovascular systems, systemic circulation, peripheral circulation, blood and neuromuscular units and muscle metabolism. The self-paced 6MWT assesses the sub- maximal level of functional capacity and will better reflect the functional exercise level for daily activities. ANOVA parameters estimates (LS Means and 90 % confidence intervals) for the overall treatment difference was analysed.</description>
          <population>All subjects in Full Analysis Set population who performed atleast one 6MWT test at Day 360, before the study was early terminated.</population>
          <units>maximal distance walked (meters)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="475" spread="119"/>
                    <measurement group_id="O2" value="453" spread="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment effect was analysed using ANOVA parameter estimates (Least Squares Means and 95 % Confidence Intervals) for the overall treatment difference for maximun distance walked on Day 360.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Least Squares Mean</param_type>
            <param_value>28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54</ci_lower_limit>
            <ci_upper_limit>110.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Extended Long-term Follow-up Endpoint: Respiratory Functioning (FEV1) at Day 360</title>
        <description>Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.</description>
        <time_frame>Day 360</time_frame>
        <population>Subjects from Full Analysis Set population attending Day 360 visit.</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Extended Long-term Follow-up Endpoint: Respiratory Functioning (FEV1) at Day 360</title>
          <description>Measuring FEV1 (forced expiratory volume in 1 second) assessed pulmonary function (airway obstruction, bronchoconstriction or bronchodilation). FEV1 is the volume exhaled during the first second of a forced expiratory manoeuvre, starting from the level of total lung capacity.</description>
          <population>Subjects from Full Analysis Set population attending Day 360 visit.</population>
          <units>%FEV1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.4" spread="31.8"/>
                    <measurement group_id="O2" value="72.0" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Post-Hoc Analyses Related to the Use of Concomitant Glucocorticoids Medications and Mortality at D28</title>
        <description>The overall use of concomitant glucocorticoids treatment in both study treatment groups (active and placebo) were analysed.</description>
        <time_frame>Day 28</time_frame>
        <population>Subjects who received at least 1 dose of concomitant glucocorticoids during days 0-28</population>
        <group_list>
          <group group_id="O1">
            <title>FP-1201-lyo 10 μg</title>
            <description>FP-1201-lyo 10 μg (Interferon beta-1a) for 6 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo for 6 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-Hoc Analyses Related to the Use of Concomitant Glucocorticoids Medications and Mortality at D28</title>
          <description>The overall use of concomitant glucocorticoids treatment in both study treatment groups (active and placebo) were analysed.</description>
          <population>Subjects who received at least 1 dose of concomitant glucocorticoids during days 0-28</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Use of concomitant glucocorticoids</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1"/>
                    <measurement group_id="O2" value="64.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mortality, with concomitant glucocorticoids</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7"/>
                    <measurement group_id="O2" value="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mortality, without concomitant glucocorticoids</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="66"/>
                    <count group_id="O2" value="54"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The Adverse Event (AE) reporting period extended up to study Day 28. In accordance with the protocol, the investigators reported AEs occurring after Day 28 only if the investigator considered a causal relationship with the study drug. All deaths were reported as SAEs throughout the study, up until Day 360.</time_frame>
      <desc>The &quot;Serious Adverse Event&quot; list and the &quot;Other (Not including Serious) Adverse Event&quot; list present all reported Treatment Emergent Adverse Events (defined as an AE that begins or that worsens in severity after at least one dose of study drug). In 3 study subjects a non-treatment emergent SAE began before first dose of the study drug (included in mortality numbers because these SAEs led to death )</desc>
      <group_list>
        <group group_id="E1">
          <title>FP-1201-lyo 10 μg</title>
          <description>FP-1201-lyo 10 μg (Interferon beta-1a) will be administered once daily as an intravenous bolus injection for 6 days.
Investigational product is lyophilisate for solution for injection which will be reconstituted in water for injection.
Interferon beta-1a: Investigational drug</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo will be administered once daily as an intravenous bolus injection for 6 days.
Investigational placebo product is lyophilisate for solution for injection which will be reconstituted in water for injection.
Placebo: Placebo for investigational drug</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="77" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="77" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CARDIAC DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PULSELESS ELECTRICAL ACTIVITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>TORSADE DE POINTES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GASTRITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL NECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>INTRA-ABDOMINAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="144"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CONDITION AGGRAVATED</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DISEASE PROGRESSION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BRAIN DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ACUTE HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC HEPATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>EMPYEMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DISSEMINATED TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER MENINGOENCEPHALITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MENINGITIS ASPERGILLUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMONIA INFLUENZAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PSEUDOMONAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SYSTEMIC CANDIDA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANASTOMOTIC LEAK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BAROTRAUMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DELAYED RECOVERY FROM ANAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ANASTOMOTIC COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL ANASTOMOTIC LEAK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>VASCULAR ACCESS COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BIOPSY BONE MARROW ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYELOID LEUKAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ADENOCARCINOMA OF THE CERVIX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CHOLANGIOCARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>COLORECTAL CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DIFFUSE LARGE B-CELL LYMPHOMA RECURRENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LUNG ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>METASTASES TO KIDNEY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>METASTASES TO LIVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>METASTASES TO LUNG</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>NEUROENDOCRINE CARCINOMA OF THE SKIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SMALL CELL LUNG CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CRITICAL ILLNESS POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BASAL GANGLIA HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BRAIN HYPOXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BRAIN INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CEREBRAL VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPOXIC-ISCHAEMIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>INTRAVENTRICULAR HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>QUADRIPLEGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>POST INFECTION GLOMERULONEPHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RENAL IMPAIRMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LARYNGEAL OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMOMEDIASTINUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ASPIRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CHRONIC RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PULMONARY THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT CONGESTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS EMPHYSEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>RENAL REPLACEMENT THERAPY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>WITHDRAWAL OF LIFE SUPPORT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>EXTRACORPOREAL MEMBRANE OXYGENATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GASTRIC OPERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LAPAROTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>SHOCK HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SHOCK</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIC SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="109" subjects_at_risk="144"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="144"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOSIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DISSEMINATED INTRAVASCULAR COAGULATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HAEMOLYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HISTIOCYTOSIS HAEMATOPHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MICROCYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="144"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CARDIAC DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA SUPRAVENTRICULAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ATRIAL TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK RIGHT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CYANOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTROPHIC CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVAL OEDEMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DIPLOPIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>EYE DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PUPILS UNEQUAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ULCERATIVE KERATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="144"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GASTRIC HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ILEUS PARALYTIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ABDOMINAL COMPARTMENT SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MOUTH HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>REGURGITATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="144"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CONDITION AGGRAVATED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GENERALISED OEDEMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPERTHERMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SYSTEMIC INFLAMMATORY RESPONSE SYNDROME</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPOTHERMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ADVERSE DRUG REACTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CATHETER SITE NECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DISEASE RECURRENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DRUG WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPERTHERMIA MALIGNANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATOCELLULAR INJURY</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="144"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CHOLESTASIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HEPATIC FUNCTION ABNORMAL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ACUTE HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HEPATORENAL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HEPATOTOXICITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>JAUNDICE CHOLESTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LIVER INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="144"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED SEPSIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PSEUDOMONAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CANDIDA INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ENTEROBACTER PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>IMPETIGO</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LUNG INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMONIA INFLUENZAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SUPERINFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SYSTEMIC CANDIDA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ASPERGILLUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BACTERIAL DISEASE CARRIER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BRONCHOPULMONARY ASPERGILLOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CANDIDA PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CANDIDURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ENTEROCOCCAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>EPIGLOTTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>FUNGAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GENITAL HERPES SIMPLEX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HERPES SIMPLEX PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>INFECTIOUS PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LYMPHANGITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>OTITIS EXTERNA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PANCREATIC ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS JIROVECII PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ESCHERICHIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMONIA VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PULMONARY SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RENAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SPUTUM PURULENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS SEPTIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>TINEA CRURIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>VULVOVAGINITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ENDOTRACHEAL INTUBATION COMPLICATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC LEAK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BAROTRAUMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>TRACHEAL INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ANIMAL BITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>EAR INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>FACE INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>FOREIGN BODY ASPIRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>JOINT INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MECHANICAL VENTILATION COMPLICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>TENDON RUPTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>TRANSFUSION REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>WOUND HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD CREATINE PHOSPHOKINASE INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD CHLORIDE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD LACTIC ACID INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM INCREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD SODIUM INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>OXYGEN SATURATION DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ANTICOAGULATION DRUG LEVEL INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD IRON DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD LACTATE DEHYDROGENASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD PHOSPHORUS DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD POTASSIUM DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD TRIGLYCERIDES INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BLOOD UREA INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM TEST POSITIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>EJECTION FRACTION DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ELECTROCARDIOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ELECTROENCEPHALOGRAM ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>EOSINOPHIL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MYOGLOBIN BLOOD INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PO2 DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RED BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SPLEEN SCAN ABNORMAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERNATRAEMIA</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="144"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>FLUID OVERLOAD</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="144"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>METABOLIC ALKALOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ALKALOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>FLUID RETENTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>FOOD INTOLERANCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GOUT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPERAMMONAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPERPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>OVERWEIGHT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RHABDOMYOLYSIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MIXED CONNECTIVE TISSUE DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>MYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>KAPOSI'S SARCOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CRITICAL ILLNESS POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>NERVOUS SYSTEM DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYDROCEPHALUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SEDATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>VOCAL CORD PARALYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>AGITATION</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DISORIENTATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HALLUCINATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>NIGHTMARE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RESTLESSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="144"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="144"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CHRONIC KIDNEY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RENAL INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="144"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="144"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY DISTRESS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMOMEDIASTINUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ASPIRATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPERCAPNIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>INCREASED BRONCHIAL SECRETION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PULMONARY FIBROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ATELECTASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HAEMOTHORAX</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LARYNGEAL DYSPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LUNG CONSOLIDATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX SPONTANEOUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ACIDOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ALKALOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>STRIDOR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RASH GENERALISED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DERMATITIS ALLERGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ECCHYMOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SKIN DISCOLOURATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SKIN NECROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SKIN ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>RENAL REPLACEMENT THERAPY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ENDOTRACHEAL INTUBATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>EXTRACORPOREAL MEMBRANE OXYGENATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GASTRECTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>GASTROSTOMY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>TRACHEOSTOMY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="144"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SHOCK HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HAEMODYNAMIC INSTABILITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>VASCULAR OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="144"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="152"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="144"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="152"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>As the study was terminated early, only a limited amount of data was available at Day 180 and Day 360.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Faron Pharmaceuticals</organization>
      <phone>+3584005529411</phone>
      <email>medical@faron.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

